ANAVEX LIFE SCIENCES C

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

06 May 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

01 May 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

30 Apr 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

23 Apr 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

21 Apr 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

05 Apr 2025 11:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

31 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

24 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

12 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

05 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

27 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

15 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

13 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

26 Dec 2024 12:00:28 By NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

24 Dec 2024 09:45:04 By NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

23 Dec 2024 09:57:16 By NetDania Notify

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

23 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

23 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

16 Dec 2024 07:30:00 By Nasdaq GlobeNewswire